BofA/Merrill Lynch Downgrades Roche (RHHBY) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts RHHBY Hot Sheet
Price: $60.94 +2.97%
Rating Summary:
5 Buy, 8 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
5 Buy, 8 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
BofA/Merrill Lynch analyst Graham Perry downgraded Roche (OTC: RHHBY) from Buy to Neutral with a price target of $34.00 (from $35.00).
For an analyst ratings summary and ratings history on Roche click here. For more ratings news on Roche click here.
Shares of Roche closed at $30.67 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Double Downgrades Aardvark Therapeutics Inc (AARD) to Market Perform
- Kraft Heinz Company (KHC) PT Raised to $24 at Jefferies
- Flutter Entertainment (FLUT) PT Lowered to $124 at Stifel
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
